CBD-Dominant Cannabis Extract Improved Multiple Symptoms in Children With Moderate to Severe Autism | Research

The takeaway

A CBD-dominant extract (33:1 CBD:THC) improved communication, attention, aggression, and quality of life in 30 children with moderate to severe autism.

Families and clinicians considering cannabinoids for autism, and researchers designing trials.

CBD-dominant extract improved communication, attention, and behavior in 30 children with ASD

What the researchers found

Thirty children (5-18) with moderate-severe ASD showed improvements in communication, attention, learning, eye contact, and reduced aggression. Both clinical and parental assessments confirmed improvements with minimal adverse effects.

Why it matters

Current autism pharmacotherapy is limited. If CBD-dominant extracts safely improve core symptoms, they could fill a major treatment gap.

The numbers in context

30 patients aged 5-18. CBD:THC ratio 33:1. Improvements in communication, attention, learning, eye contact. Reduced aggression. Minimal adverse effects.

How the study worked

Retrospective observational cohort of 30 ASD patients aged 5-18 treated with CBD-dominant extract (33:1 CBD:THC) at individualized doses.

What this study cannot tell us

No placebo control. Retrospective. Small sample. Individualized dosing. Unblinded assessments.

How to read the evidence

Uncontrolled observational study with small sample and no blinding.

When this study was published

Published in 2024.

The bigger picture

Multiple observational studies suggest cannabinoid benefits in autism, but large placebo-controlled trials are still lacking.

Questions still open

Would a placebo-controlled trial confirm these improvements?
What is the optimal CBD:THC ratio for autism?

Common questions

Can CBD help with autism?

In this study, a CBD-dominant extract improved multiple symptoms in 30 children, but the lack of placebo control means results need confirmation.

Is CBD safe for children with autism?

Minimal adverse effects were reported in this study of 30 children aged 5-18, but larger controlled trials are needed.

Read the original research

Clinical and Family Implications of Cannabidiol (CBD)-Dominant Full-Spectrum Phytocannabinoid Extract in Children and Adolescents with Moderate to Severe Non-Syndromic Autism Spectrum Disorder (ASD): An Observational Study on Neurobehavioral Management.

Pharmaceuticals (Basel, Switzerland), 17(6)

View on PubMed ↗Publisher’s paper ↗

Citation

Mazza, Jeanne Alves de Souza; Ferreira, Lisiane Seguti; Martins-Vieira, Alice de Faria; Beserra, Doris Day Lopes; Rodrigues, Victor Alves; Malcher-Lopes, Renato; Caixeta, Fabio V. (2024). Clinical and Family Implications of Cannabidiol (CBD)-Dominant Full-Spectrum Phytocannabinoid Extract in Children and Adolescents with Moderate to Severe Non-Syndromic Autism Spectrum Disorder (ASD): An Observational Study on Neurobehavioral Management.. Pharmaceuticals (Basel, Switzerland), 17(6). https://doi.org/10.3390/ph17060686